Fulgent Genetics

Traded on the St. Petersburg Stock Exchange
Fulgent Genetics is an American technology company. It develops a technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, genetic diagnostics tools, and integrated laboratory processes. The company was founded in 2011 and is headquartered in Temple City, California.
Fulgent Genetics stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Fulgent Genetics balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Fulgent Genetics cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Fulgent Genetics multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Fulgent Genetics profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Fulgent Genetics assets
Fulgent Genetics cash flows

Fulgent Genetics dividend policy

The company doesn't provide dividend

Fulgent Genetics shares

TickerNameTypeNominal valueISINPrice
FLGT:USFulgent GeneticsCommon share-US3596641098$23.8
Fulgent Genetics news
04.05.2022
Fulgent Genetics' GAAP net income for the 3 months of 2022 was $153.557 million, down 23.5% from $200.691 million in the previous year. Revenue decreased 10.9% to $320.268 million from $359.429 million a year earlier.
Source: {source} pictogram fulgentgenetics.gcs-web.com
Pictogram next
19.04.2022
Fulgent Genetics acquires Inform Diagnostics for $170 million. The company provides diagnostic services in gastrointestinal pathology, dermatopathology, urological pathology, hematopathology and more. The deal is scheduled to close in Q2 2022.
Source: {source} pictogram ir.fulgentgenetics.com
Pictogram next
24.02.2022
Net income of Fulgent Genetics under GAAP for 2021 was $506.239 million, up 2.4 times from $214.31 million in the previous year. Revenue increased 2.4 times to $992.584 million from $421.712 million a year earlier.
Source: {source} pictogram fulgentgenetics.gcs-web.com
Pictogram next
10.11.2021
Net income of Fulgent Genetics under GAAP for 9M 2021 was $403.025 million, up 8.4 times from $48.003 million in the previous year. Revenue increased 5.8 times to $740.913 million from $126.734 million a year earlier.
Source: {source} pictogram fulgentgenetics.gcs-web.com
Pictogram next
All Fulgent Genetics news
General information
Company nameFulgent Genetics
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Life Sciences Tools & Services / Life Sciences Tools & Services
Business address4978 Santa Anita Avenue Suite 205 Temple City, CA 91780 United States
Mailing address4978 Santa Anita Avenue Suite 205 Temple City, CA 91780 United States
Websitefulgentgenetics.gcs-web.com
Information disclosurewww.sec.gov